Abstract 5784
Background
About 20-30% patients with newly diagnosed multiple myeloma (ND MM) experience damage to kidneys and in 2-4% of cases, hemodialysis is required. NT‐proBNP synthesize in atria and ventricles cardiomyocytes and excreted by the kidney. The purpose of this work was to analyze the predictive utility of NT-proBNP in patients with ND MM, complicated by severe dialysis-dependent renal failure (RF).
Methods
Between 10.2016 and 07.2017, 20 patients with ND MM and terminal RF enrolled in this prospective study. Exclusion criteria were diagnosed at AL-amyloidosis and a significant cardiac pathology. Samples for NT‐proBNP analysis were collected before antimyeloma chemotherapy and not earlier than 36 hours after hemodialysis. The ROC analysis determined the area under the error curve as 0.75 (0.52-0.97), and the cut-off point for the OS was an NT-proBNP concentration of 7036 pg/ml (sensitivity 79%; specificity 44%). According to these data, the patients were divided into two groups, depending on the NT-proBNP value less than (n = 9) or more than (n = 11) 7000 pg/ml for the subsequent analysis.
Results
The median age of the patients was 67 years (range, 63-76). Median of estimated glomerular filtration CKD-EPI rate was 4.0 (IQR 4.0-5.0) ml/min/1.73 m2. The only difference between the groups was the volume of residual diuresis 1250 (550-2500) vs. 50.0 (37.5-1038) ml/day (P = 0.036). As induction therapies, 11 (55%) patients underwent a VCD regimen, 7 (35%) - VD), and 2 (10%) - VMP. The ASCT accomplished in 1 patient. The renal response was documented in 4 (25.0%) cases including one complete response. With a median follow-up of 17.3 months, the overall OS was 48.5±11.5%. The 18-month OS for comparison groups were 76.6±14.8% and 27.3±13.4% (P = 0.020), respectively. There were no causes of death due to cardiovascular complications.
Conclusions
According to our data, NT-proBNP > 7400 pg/ml are associated with the severity of kidney damage and the risk of non-cardiac mortality in ND MM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2490 - Gender effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of anamorelin (ANAM) in healthy volunteers and cancer patients with cachexia
Presenter: Stein Kaasa
Session: Poster Display session 1
Resources:
Abstract
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
1925 - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients
Presenter: Claudio Chini
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract